백혈병 치료제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of leukemia therapeutics Market

The global leukemia therapeutics market is experiencing steady growth due to the increasing prevalence of leukemia, rising healthcare expenditure, growing adoption of advanced cancer treatments, and increasing investments in research and development. The global leukemia therapeutics market size was valued at USD 23.82 billion in 2025. The market is projected to grow from USD 25.67 billion in 2026 to USD 46.75 billion by 2034, exhibiting a CAGR of 7.78% during 2026-2034. North America dominated the market with a 45.5% share in 2025, supported by advanced healthcare infrastructure, strong R&D activity, and the presence of leading pharmaceutical companies.

Leukemia is a blood cancer associated with abnormal development of white blood cells in the bone marrow. Major types include acute myeloid leukemia (AML), chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), and acute lymphocytic leukemia (ALL). Treatment options include chemotherapy, targeted therapy, immunotherapy, radiotherapy, and adoptive cell therapies, with treatment selection depending on disease type and patient-specific factors.

Market Definition and Scope

The leukemia therapeutics market includes medicines and treatment approaches used for the management of different forms of leukemia. Chemotherapy remains an important treatment approach because therapeutic agents can circulate through the bloodstream and reach abnormal blood cells throughout the body. Targeted therapies directly act on specific cancer-related mechanisms and are increasingly being incorporated into treatment strategies.

The market scope covers leukemia therapeutics by type of leukemia, treatment type, route of administration, and distribution channel. It includes CML, CLL, ALL, AML, and other leukemia types, along with chemotherapy, targeted therapy, immunotherapy, and other treatment categories. Distribution channels include hospital pharmacies, retail pharmacies, and other channels.

Market Dynamics

Drivers

The increasing incidence of leukemia is a major factor supporting market growth. A growing patient population across different leukemia types is increasing the need for effective therapeutic options. Rising awareness of cancer treatment and improved diagnosis are also contributing to greater demand for leukemia therapeutics.

Another important driver is rising R&D spending and new product launches. Pharmaceutical companies are investing in innovative medicines and combination therapies to improve treatment outcomes. Continued regulatory approvals and clinical development programs are expanding available treatment options for leukemia patients.

Trends

The development of innovative therapies is a major market trend. Companies and research institutions are exploring immune-based treatments such as CAR T-cell therapies, immune checkpoint blockers, and bispecific T-cell engagers. Bone marrow transplantation, stem cell therapies, and natural killer cell-based immunotherapy are also areas of ongoing development.

The increasing use of personalized treatment approaches and advanced diagnostic technologies, including artificial intelligence-based tools for leukemia detection, is further contributing to innovation across the market.

Restraints

The side effects and adverse reactions associated with leukemia therapeutics can limit market growth. Chemotherapy may cause infections, fatigue, hair loss, and skin-related problems, while targeted therapies can be associated with gastrointestinal and other adverse effects. These treatment-related challenges can influence patient acceptance and therapeutic decision-making.

Impact of COVID-19

The COVID-19 pandemic affected healthcare systems, treatment schedules, clinical activities, and supply chains. However, the need for cancer treatment continued during the pandemic. Pharmaceutical companies and healthcare providers maintained efforts to develop and deliver leukemia therapies, while research and innovation in cancer treatment continued despite operational challenges.

Segmentation Analysis

By type of leukemia, the market includes CML, CLL, ALL, AML, and others. CLL and AML represent important segments due to their substantial patient populations, while treatment demand for CML remains significant, particularly in developed markets.

By treatment type, chemotherapy is expected to retain the largest market share as an established first-line treatment option. Targeted therapy represents a rapidly developing category due to its ability to address specific cancer mechanisms, while immunotherapy is gaining importance through advanced immune-based approaches.

By route of administration, injectable therapies held the largest market share due to the widespread use of injectable chemotherapy and targeted treatments and their rapid absorption. Oral therapies provide a convenient alternative and represent an important segment.

By distribution channel, hospital pharmacies are expected to maintain a leading position because hospitals are primary centers for leukemia diagnosis and treatment.

Regional Insights

North America leads the global leukemia therapeutics market, with the regional market reaching USD 6.92 billion in 2025. Strong healthcare infrastructure, high healthcare expenditure, increasing leukemia prevalence, and significant pharmaceutical R&D activity support regional growth.

Europe represents an important market due to the adoption of advanced leukemia therapies and increasing cancer awareness. Asia Pacific is expected to experience rapid growth, supported by a large patient population, improving healthcare access, product launches, and increasing cancer-treatment reimbursement in countries such as China and India.

Latin America and the Middle East & Africa represent developing markets where increasing healthcare expenditure and greater awareness of timely cancer treatment are expected to support future expansion.

Competitive Landscape

The leukemia therapeutics market includes established pharmaceutical companies with broad oncology portfolios and emerging companies developing innovative therapies. Key players include Pfizer Inc., Novartis, Lupin Ltd., Amgen Inc., AbbVie, Johnson & Johnson Services, Inc., Bristol-Myers Squibb, F. Hoffmann-La Roche, Takeda Pharmaceutical Co Ltd, and Sanofi/Genzyme Corporation.

Companies are focusing on new product approvals, combination therapies, immunotherapies, clinical development, and expansion of treatment portfolios. Recent developments include regulatory approvals for Onureg, Venclexta combinations, and IMBRUVICA-based treatment approaches.

Report Coverage

This report provides a comprehensive analysis of the global leukemia therapeutics market, covering market size and market value for 2025, 2026, and 2034, CAGR, leukemia types, treatment types, routes of administration, distribution channels, regional analysis, market dynamics, COVID-19 impact, competitive landscape, key companies, and recent industry developments.

Conclusion

Growing from USD 23.82 billion in 2025 to USD 25.67 billion in 2026 and reaching USD 46.75 billion by 2034, the global leukemia therapeutics market is expected to expand at a CAGR of 7.78%. Increasing leukemia incidence, rising R&D investments, new product launches, and the development of targeted and immune-based therapies are key factors supporting market expansion. North America, with a 45.5% market share in 2025, remains the leading regional market, while innovations in personalized therapies, immunotherapy, and advanced treatment approaches continue to shape the future of leukemia therapeutics.

Unit Value (USD Billion)

Segmentation Type of Leukemia, Treatment Type, Route of Administration, Distribution Channels, and Geography

By Type of Leukemia

• Chronic Myeloid Leukemia (CML)
• Chronic Lymphocytic Leukemia (CLL)
• Acute Lymphocytic Leukemia (ALL)
• Acute Myeloid Leukemia (AML)
• Others

By Treatment Type

• Chemotherapy
• Targeted Therapy
• Immunotherapy
• Others

By Route of Administration

• Oral
• Injectable

By Distribution Channels

• Hospital Pharmacy
• Retail Pharmacy
• Others

By Geography

• North America
  • By Type of Leukemia
  • By Treatment Type
  • By Route of Administration
  • By Distribution Channels
  • By Country
• The U.S. (By Type of Leukemia)
• Canada (By Type of Leukemia)
• Europe
  • By Type of Leukemia
  • By Treatment Type
  • By Route of Administration
  • By Distribution Channels
  • By Country/ Sub-Region
• The U.K. (By Type of Leukemia)
• Germany (By Type of Leukemia)
• France (By Type of Leukemia)
• Italy (By Type of Leukemia)
• Spain (By Type of Leukemia)
• Rest of Europe (By Type of Leukemia)
• Asia Pacific
  • By Type of Leukemia
  • By Treatment Type
  • By Route of Administration
  • By Distribution Channels
  • By Country/ Sub-Region
• Japan (By Type of Leukemia)
• China (By Type of Leukemia)
• India (By Type of Leukemia)
• Australia (By Type of Leukemia)
• Rest of Asia Pacific (By Type of Leukemia)
• Latin America
  • By Type of Leukemia
  • By Treatment Type
  • By Route of Administration
  • By Distribution Channels
  • By Country/ Sub-Region
• Brazil (By Type of Leukemia)
• Mexico (By Type of Leukemia)
• Rest of Latin America (By Type of Leukemia)
• The Middle East & Africa
  • By Type of Leukemia
  • By Treatment Type
  • By Route of Administration
  • By Distribution Channels
  • By Country/ Sub-Region
• GCC (By Type of Leukemia)
• South Africa (By Type of Leukemia)
• Rest of the Middle East & Africa (By Type of Leukemia)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Pipeline Analysis, Key Players
• 4.2. Prevalence of Leukemia, Key Countries, 2025
• 4.3. Key Industry Developments (Mergers, Acquisition, etc.)
• 4.4. Impact of Covid-19 on the Leukemia Therapeutics Market

5. Global Leukemia Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Type of Leukemia
  • 5.2.1. Chronic Myeloid Leukemia (CML)
  • 5.2.2. Chronic Lymphocytic Leukemia (CLL)
  • 5.2.3. Acute Lymphocytic Leukemia (ALL)
  • 5.2.4. Acute Myeloid Leukemia (AML)
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Treatment Type
  • 5.3.1. Chemotherapy
  • 5.3.2. Targeted Therapy
  • 5.3.3. Immunotherapy
  • 5.3.4. Others
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Injectable Mode
  • 5.4.2. Oral Mode
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacies
  • 5.5.2. Retail Pharmacies
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Leukemia Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis - By Type of Leukemia
  • 6.2.1. Chronic Myeloid Leukemia (CML)
  • 6.2.2. Chronic Lymphocytic Leukemia (CLL)
  • 6.2.3. Acute Lymphocytic Leukemia (ALL)
  • 6.2.4. Acute Myeloid Leukemia (AML)
  • 6.2.5. Others
• 6.3. Market Analysis - By Treatment Type
  • 6.3.1. Chemotherapy
  • 6.3.2. Targeted Therapy
  • 6.3.3. Immunotherapy
  • 6.3.4. Others
• 6.4. Market Analysis - By Route of Administration
  • 6.4.1. Injectable Mode
  • 6.4.2. Oral Mode
• 6.5. Market Analysis - By Distribution Channel
  • 6.5.1. Hospital Pharmacies
  • 6.5.2. Retail Pharmacies
  • 6.5.3. Others
• 6.6. Market Analysis - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Leukemia Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis - By Type of Leukemia
  • 7.2.1. Chronic Myeloid Leukemia (CML)
  • 7.2.2. Chronic Lymphocytic Leukemia (CLL)
  • 7.2.3. Acute Lymphocytic Leukemia (ALL)
  • 7.2.4. Acute Myeloid Leukemia (AML)
  • 7.2.5. Others
• 7.3. Market Analysis - By Treatment Type
  • 7.3.1. Chemotherapy
  • 7.3.2. Targeted Therapy
  • 7.3.3. Immunotherapy
  • 7.3.4. Others
• 7.4. Market Analysis - By Route of Administration
  • 7.4.1. Injectable Mode
  • 7.4.2. Oral Mode
• 7.5. Market Analysis - By Distribution Channel
  • 7.5.1. Hospital Pharmacies
  • 7.5.2. Retail Pharmacies
  • 7.5.3. Others
• 7.6. Market Analysis - By Country/Sub-Region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Rest of Europe

8. Asia Pacific Leukemia Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis - By Type of Leukemia
  • 8.2.1. Chronic Myeloid Leukemia (CML)
  • 8.2.2. Chronic Lymphocytic Leukemia (CLL)
  • 8.2.3. Acute Lymphocytic Leukemia (ALL)
  • 8.2.4. Acute Myeloid Leukemia (AML)
  • 8.2.5. Others
• 8.3. Market Analysis - By Treatment Type
  • 8.3.1. Chemotherapy
  • 8.3.2. Targeted Therapy
  • 8.3.3. Immunotherapy
  • 8.3.4. Others
• 8.4. Market Analysis - By Route of Administration
  • 8.4.1. Injectable Mode
  • 8.4.2. Oral Mode
• 8.5. Market Analysis - By Distribution Channel
  • 8.5.1. Hospital Pharmacies
  • 8.5.2. Retail Pharmacies
  • 8.5.3. Others
• 8.6. Market Analysis - By Country/Sub-Region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Rest of Asia Pacific

9. Latin America Leukemia Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis - By Type of Leukemia
  • 9.2.1. Chronic Myeloid Leukemia (CML)
  • 9.2.2. Chronic Lymphocytic Leukemia (CLL)
  • 9.2.3. Acute Lymphocytic Leukemia (ALL)
  • 9.2.4. Acute Myeloid Leukemia (AML)
  • 9.2.5. Others
• 9.3. Market Analysis - By Treatment Type
  • 9.3.1. Chemotherapy
  • 9.3.2. Targeted Therapy
  • 9.3.3. Immunotherapy
  • 9.3.4. Others
• 9.4. Market Analysis - By Route of Administration
  • 9.4.1. Injectable Mode
  • 9.4.2. Oral Mode
• 9.5. Market Analysis - By Distribution Channel
  • 9.5.1. Hospital Pharmacies
  • 9.5.2. Retail Pharmacies
  • 9.5.3. Others
• 9.6. Market Analysis - By Country/Sub-Region
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Leukemia Therapeutics Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis - By Type of Leukemia
  • 10.2.1. Chronic Myeloid Leukemia (CML)
  • 10.2.2. Chronic Lymphocytic Leukemia (CLL)
  • 10.2.3. Acute Lymphocytic Leukemia (ALL)
  • 10.2.4. Acute Myeloid Leukemia (AML)
  • 10.2.5. Others
• 10.3. Market Analysis - By Treatment Type
  • 10.3.1. Chemotherapy
  • 10.3.2. Targeted Therapy
  • 10.3.3. Immunotherapy
  • 10.3.4. Others
• 10.4. Market Analysis - By Route of Administration
  • 10.4.1. Injectable Mode
  • 10.4.2. Oral Mode
• 10.5. Market Analysis - By Distribution Channel
  • 10.5.1. Hospital Pharmacies
  • 10.5.2. Retail Pharmacies
  • 10.5.3. Others
• 10.6. Market Analysis - By Country/Sub-Region
  • 10.6.1. GCC Countries
  • 10.6.2. South Africa
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Competition Dashboard
• 11.4. Comparative Analysis - Major Players
• 11.5. Company Profiles
  • 11.5.1. Pfizer Inc.
    • 11.5.1.1. Overview,
    • 11.5.1.2. Products,
    • 11.5.1.3. SWOT analysis,
    • 11.5.1.4. Recent developments,
    • 11.5.1.5. strategies,
    • 11.5.1.6. financials (based on availability)
  • 11.5.2. Novartis
    • 11.5.2.1. Overview,
    • 11.5.2.2. Products,
    • 11.5.2.3. SWOT analysis,
    • 11.5.2.4. Recent developments,
    • 11.5.2.5. strategies,
    • 11.5.2.6. financials (based on availability)
  • 11.5.3. Sanofi/ Genzyme Corporation
    • 11.5.3.1. Overview,
    • 11.5.3.2. Products,
    • 11.5.3.3. SWOT analysis,
    • 11.5.3.4. Recent developments,
    • 11.5.3.5. strategies,
    • 11.5.3.6. financials (based on availability)
  • 11.5.4. Lupin Ltd.
    • 11.5.4.1. Overview,
    • 11.5.4.2. Products,
    • 11.5.4.3. SWOT analysis,
    • 11.5.4.4. Recent developments,
    • 11.5.4.5. strategies,
    • 11.5.4.6. financials (based on availability)
  • 11.5.5. Amgen Inc.
    • 11.5.5.1. Overview,
    • 11.5.5.2. Products,
    • 11.5.5.3. SWOT analysis,
    • 11.5.5.4. Recent developments,
    • 11.5.5.5. strategies,
    • 11.5.5.6. financials (based on availability)
  • 11.5.6. AbbVie
    • 11.5.6.1. Overview,
    • 11.5.6.2. Products,
    • 11.5.6.3. SWOT analysis,
    • 11.5.6.4. Recent developments,
    • 11.5.6.5. strategies,
    • 11.5.6.6. financials (based on availability)
  • 11.5.7. Johnson & Johnson Services, Inc.
    • 11.5.7.1. Overview,
    • 11.5.7.2. Products,
    • 11.5.7.3. SWOT analysis,
    • 11.5.7.4. Recent developments,
    • 11.5.7.5. strategies,
    • 11.5.7.6. financials (based on availability)
  • 11.5.8. Bristol-Myers Squibb
    • 11.5.8.1. Overview,
    • 11.5.8.2. Products,
    • 11.5.8.3. SWOT analysis,
    • 11.5.8.4. Recent developments,
    • 11.5.8.5. strategies,
    • 11.5.8.6. financials (based on availability)
  • 11.5.9. F. Hoffmann-La Roche
    • 11.5.9.1. Overview,
    • 11.5.9.2. Products,
    • 11.5.9.3. SWOT analysis,
    • 11.5.9.4. Recent developments,
    • 11.5.9.5. strategies,
    • 11.5.9.6. financials (based on availability)
  • 11.5.10. Takeda Pharmaceutical Co Ltd
    • 11.5.10.1. Overview,
    • 11.5.10.2. Products,
    • 11.5.10.3. SWOT analysis,
    • 11.5.10.4. Recent developments,
    • 11.5.10.5. strategies,
    • 11.5.10.6. financials (based on availability)
  • 11.5.11. Sanofi/ Genzyme Corporation
    • 11.5.11.1. Overview,
    • 11.5.11.2. Products,
    • 11.5.11.3. SWOT analysis,
    • 11.5.11.4. Recent developments,
    • 11.5.11.5. strategies,
    • 11.5.11.6. financials (based on availability)